免疫治疗联合抗血管生成药物在晚期宫颈癌上的疗效
1. Insinga RP, Perez G, Wheeler CM,et al. Incident cervical HPV infections in young women: transition probabilitiesfor CIN and infection clearance[J]. Cancer Epidemiol Biomarkers Prev, 2011,20(2): 287-296.
2. Tewari KS, Sill MW, Penson RT,et al. Bevacizumab for advanced cervical cancer: final overall survival andadverse event analysis of a randomised, controlled, openlabel, phase 3 trial(Gynecologic Oncology Group 240) [J]. Lancet, 2017, 390(10103): 1654-1663.
3. Hong AM, Vilain RE, Romanes S,et al. PD-L1 expression in tonsillar cancer is associated with humanpapillomavirus positivity and improved survival: implications for anti-PD1clinical trials[J]. Oncotarget, 2016, 7(47): 77010-77020.
4. Jean-Sebastien Frenel et al.Safety and Efficacy of Pembrolizumab in Advanced,Programmed Death Ligand 1–Positive CervicalCancer. JOURNAL OF CLINICAL ONCOLOGY;2017;10(20).
5. Chunyan Lan, MDet al.Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): AMulticenter, Open-Label, Single-Arm, Phase II Trial[J]. ASCO,2020.
6. Claire F Friedman et al. PhaseII study of atezolizumab in combination with bevacizumab in patients withadvanced cervical cancer . J Immunother Cancer ;2020 Oct;8(2).
精彩推荐:
- End -